Novo Seeds Launches Tribune Therapeutics to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases

  • Company co-created and funded by Novo Holdings and HealthCap
  • Breakthrough asset in-licensed from Norway’s foremost tech transfer office, Inven2
  • João Ribas and Jørgen Søberg Petersen from Novo Seeds will join the Board of Directors

Copenhagen, Denmark, 2 June 2021 – Novo Holdings today announces that it has founded and invested in Tribune Therapeutics (“Tribune”), a company set up to exploit a novel, pan-antifibrotic mechanism across a wide range of indications. This follows a period of company creation, with close involvement by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, in collaboration with HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH